Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

References

• Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010); 33(8):828-33; PMID:20842054; http://dx.doi.org/10.1097/CJI.0b013e3181eec14c
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013); 36(7):382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010); 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011); 364(26):2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003); 100(14):8372-7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003); 100(8):4712-7; PMID:12682289; http://dx.doi.org/10.1073/pnas.0830997100
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009); 9(3):162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008); 181(8):5791-802; PMID:18832739; http://dx.doi.org/10.4049/jimmunol.181.8.5791
   PubMed Web of Science ®Google Scholar
• Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol (2008); 83(5):1136-44; PMID:18285406; http://dx.doi.org/10.1189/jlb.0907611
   PubMed Web of Science ®Google Scholar
• Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood (2008); 111(12):5457-66; PMID:18375791; http://dx.doi.org/10.1182/blood-2008-01-136895
   PubMed Web of Science ®Google Scholar
• Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001); 193(6):727-40; PMID:11257139; http://dx.doi.org/10.1084/jem.193.6.727
   PubMed Web of Science ®Google Scholar
• Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood (2002); 99(1):111-20; PMID:11756160; http://dx.doi.org/10.1182/blood.V99.1.111
   PubMed Web of Science ®Google Scholar
• Li F, Xiang Y, Potter J, Dinavahi R, Dang CV, Lee LA. Conditional deletion of c-myc does not impair liver regeneration. Cancer Res (2006); 66(11):5608-12; PMID:16740696; http://dx.doi.org/10.1158/0008-5472.CAN-05-4242
   PubMed Web of Science ®Google Scholar
• Richardsen E, Uglehus RD, Johnsen SH, Busund LT, Macrophage-Colony Stimulating Factor (CSF1) Predicts Breast Cancer Progression and Mortality. Anticancer research (2015); 35(2):865-74; PMID:25667468
   PubMed Web of Science ®Google Scholar
• Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol (2008); 26(16):2707-16; PMID:18509183; http://dx.doi.org/10.1200/JCO.2007.15.6521
   PubMed Web of Science ®Google Scholar
• Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood (2010); 115(7):1461-71; PMID:20008303; http://dx.doi.org/10.1182/blood-2009-08-237412
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother (2012); 35(9):702-10; PMID:23090079; http://dx.doi.org/10.1097/CJI.0b013e318272569b
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res (2014); 74(18):5057-69; PMID:25082815; http://dx.doi.org/10.1158/0008-5472.CAN-13-3723
   PubMed Web of Science ®Google Scholar
• Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther (2009); 8(11):3151-61; PMID:19887542; http://dx.doi.org/10.1158/1535-7163.MCT-09-0255
   PubMed Web of Science ®Google Scholar
• Patel S, Player MR. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Current topics in medicinal chemistry (2009); 9(7):599-610; PMID:19689368; http://dx.doi.org/10.2174/156802609789007327
   PubMed Web of Science ®Google Scholar
• Chitu V, Nacu V, Charles JF, Henne WM, McMahon HT, Nandi S, Ketchum H, Harris R, Nakamura MC, Stanley ER. PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts. Blood (2012); 120(15):3126-35; PMID:22923495; http://dx.doi.org/10.1182/blood-2012-04-425595
   PubMed Web of Science ®Google Scholar
• Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res (2013); 73(9):2782-94; PMID:23418320; http://dx.doi.org/10.1158/0008-5472.CAN-12-3981
   PubMed Web of Science ®Google Scholar
• Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber TG, West BL, Bollag G, Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res (2014); 74(1):153-61; PMID:24247719; http://dx.doi.org/10.1158/0008-5472.CAN-13-1816
   PubMed Web of Science ®Google Scholar
• Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, Segall JE. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med (2012); 18:519-27; PMID:22294205; http://dx.doi.org/10.2119/molmed.2011.00217
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011); 1(1):54-67; PMID:22039576; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
   PubMed Web of Science ®Google Scholar
• Ries CH, Hoves S, Cannarile MA, Ruttinger D. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol (2015); 23:45-51; PMID:26051995; http://dx.doi.org/10.1016/j.coph.2015.05.008
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010); 3:15-25; PMID:20616954; http://dx.doi.org/10.2147/OTT.S4833
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012); 12(4):253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015); 373(1):23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015); 372(21):2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013); 369(2):134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013); 369(2):122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2013); 73(3):1128-41; PMID:23221383; http://dx.doi.org/10.1158/0008-5472.CAN-12-2731
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013); 19(10):1264-72; PMID:24056773; http://dx.doi.org/10.1038/nm.3337
   PubMed Web of Science ®Google Scholar
• Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, Daniel D. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology (2013); 2(12):e26968; PMID:24498562; http://dx.doi.org/10.4161/onci.26968
   PubMed Web of Science ®Google Scholar
• Sluijter M, van der Sluis TC, van der Velden PA, Versluis M, West BL, van der Burg SH, van Hall T. Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One (2014); 9(8):e104230; PMID:25110953; http://dx.doi.org/10.1371/journal.pone.0104230
   PubMedGoogle Scholar
• Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res (2006); 66(8):4349-56; PMID:16618760; http://dx.doi.org/10.1158/0008-5472.CAN-05-3523
   PubMed Web of Science ®Google Scholar
• Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008); 111(8):4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006); 66(2):1123-31; PMID:16424049; http://dx.doi.org/10.1158/0008-5472.CAN-05-1299
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One (2012); 7(7):e40677; PMID:22815789; http://dx.doi.org/10.1371/journal.pone.0040677
   PubMedGoogle Scholar
• Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res (2009); 69(4):1685-92; PMID:19176388; http://dx.doi.org/10.1158/0008-5472.CAN-08-2164
   PubMed Web of Science ®Google Scholar
• Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science (2008); 320(5877):807-11; PMID:18467591; http://dx.doi.org/10.1126/science.1154370
   PubMed Web of Science ®Google Scholar
• Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, Williams LT, Lin H, Stanley ER. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol (2010); 88(3):495-505; PMID:20504948; http://dx.doi.org/10.1189/jlb.1209822
   PubMed Web of Science ®Google Scholar
• Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol (2007); 178(8):5245-52; PMID:17404308; http://dx.doi.org/10.4049/jimmunol.178.8.5245
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos GK, Sakorafas GH, Kostopoulos P, Margantinis G, Tsiakos S, Terpos E, Pavlakis G, Fortun P, Arvanitidis D. Disseminated colon cancer with severe peripheral blood eosinophilia and elevated serum levels of interleukine-2, interleukine-3, interleukine-5, and GM-CSF. Surg Oncol (2005); 89(4):273-5; PMID:15726608; http://dx.doi.org/10.1002/jso.20173
   PubMed Web of Science ®Google Scholar
• Wu QD, Wang JH, Bouchier-Hayes D, Redmond HP. Neutrophil-induced transmigration of tumour cells treated with tumour-conditioned medium is facilitated by granulocyte-macrophage colony-stimulating factor. Eur J Surg (2000); 166(5):361-6; PMID:10881945; http://dx.doi.org/10.3109/110241500750008899
   PubMedGoogle Scholar
• Jubinsky PT, Short MK, Mutema G, Morris RE, Ciraolo GM, Li M. Magmas expression in neoplastic human prostate. J Mol Histol (2005); 36(1–2):69-75; PMID:15704001; http://dx.doi.org/10.1007/s10735-004-3840-8
   PubMed Web of Science ®Google Scholar
• Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S, Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast cancer research : BCR (2007); 9(1):R15; PMID:17261184; http://dx.doi.org/10.1186/bcr1648
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer cell (2009); 16(3):183-94; PMID:19732719; http://dx.doi.org/10.1016/j.ccr.2009.06.017
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013); 210(7):1389-402; PMID:23752227; http://dx.doi.org/10.1084/jem.20130066
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, D Zamarin, Y Li, B Gasmi, DH Munn, JP Allison, T Merghoub, JD Wolchok. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell reports 2015; 13:412-4; PMID:26411680; http://dx.doi.org/10.1016/j.celrep.2015.08.077
   PubMed Web of Science ®Google Scholar
• Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP, “GenePattern 2.0” Nature Genetics (2006); 38 no. 5: 500-501; http://dx.doi.org/10.1038/ng0506-500
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med Jun (2015); 25;372(26):2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Garon EB1, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med May (2015); 21;372(21):2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med Nov 5(2015); 373(19):1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar